X

Stay Connected

Sign Up for Updates

We are creating a place where we can share ideas, provide the perspective of America's biopharmaceutical companies and, most importantly, listen to you.

The latest: What they are saying: Intellectual property protections vital to COVID-19 research, development and manufacturing

By Tom Wilbur  |    February 12, 2021
Strong and reliable IP protections – including patents – have supported America’s robust innovation ecosystem by promoting discovery, development, affordability and access to new treatments and...   Read More

Preserving U.S. innovation worldwide is more important than ever

By Megan Van Etten  |    January 29, 2021
The COVID-19 pandemic has spurred unprecedented levels of innovation within the biopharmaceutical industry to combat this urgent global health crisis. PhRMA member companies are collaborating with...   Read More

The latest: What they are saying: Intellectual property protections vital to incentivize ongoing COVID-19 research and development

By Tom Wilbur  |    December 18, 2020
America’s biopharmaceutical companies are committed to COVID-19 treatment and vaccine research and development (R&D). Reliable IP protections have helped drive innovation and enhance patient...   Read More

The latest: What they are saying: Intellectual property protections vital to incentivize ongoing COVID-19 research and development

By Tom Wilbur  |    December 7, 2020
America’s biopharmaceutical companies are committed to COVID-19 treatment and vaccine research and development (R&D). Reliable IP protections have helped drive innovation and enhance patient...   Read More

New video: See how strong IP protections lead to stronger treatments for patients

By Tom Wilbur  |    November 9, 2020
Intellectual property (IP) protections, including patents, are the foundation for biopharmaceutical innovation and the development of new treatments, cures and vaccines for patients. A strong IP...   Read More

The latest: What they are saying: Intellectual property protections vital to incentivize ongoing COVID-19 research and development

By Tom Wilbur  |    October 7, 2020
America’s biopharmaceutical companies are committed to COVID-19 treatment and vaccine research and development (R&D). Reliable IP protections have helped drive innovation and enhance patient...   Read More

Why the U.S. biopharmaceutical industry is leading the charge against COVID-19

By Tom Wilbur  |    September 30, 2020
The rapid spread and impact of COVID-19 has sparked a global race to find effective treatments and preventative vaccines with the U.S. biopharmaceutical industry leading the charge. America’s...   Read More

New Graphic: Public-Private collaboration fuels the U.S. biopharmaceutical ecosystem

By Jocelyn Ulrich  |    September 16, 2020
America’s biopharmaceutical companies are at the heart of a robust research and development (R&D) ecosystem that develops more innovative medicines than any other country in the world. In recent...   Read More

The latest: What they are saying: Intellectual property protections vital to incentivize ongoing COVID-19 research and development

By Tom Wilbur  |    September 8, 2020
America’s biopharmaceutical companies are committed to COVID-19 treatment and vaccine research and development (R&D). Reliable IP protections have helped drive innovation and enhance patient...   Read More

The latest: What they are saying: Intellectual property protections vital to incentivize ongoing COVID-19 research and development

By Tom Wilbur  |    August 24, 2020
America’s biopharmaceutical companies are committed to COVID-19 treatment and vaccine research and development (R&D). Reliable IP protections have helped drive innovation and enhance patient...   Read More

Search the Catalyst

View Posts by Topic

see all

View Posts by Date

see all

Subscribe to Email Updates